MedTrace Logo

Olive Leaf Extract in Handball Players

NCT07371052 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2026-01-27

No results posted yet for this study

Summary

Olive leaf extract (OLE) is a natural supplement rich in phenolic compounds, especially oleuropein, which has antioxidant properties that may support recovery after physical exercise. While OLE has been studied for various health-related effects, its potential impact on exercise recovery and performance in elite athletes remains unclear.

This randomized, double-blind, placebo-controlled study was designed to evaluate the effects of four weeks of OLE supplementation on physical performance, sleep quality, and post-exercise muscle soreness in elite male handball players aged 18 to 25 years. Participants were randomly assigned to receive either a daily OLE supplement (500 mg, standardized to 25% oleuropein) or a placebo for four weeks. Physical performance, sleep quality, and muscle soreness were assessed at baseline, during the intervention, and at the end of the study period. Muscle soreness was additionally evaluated at 12 and 24 hours following exercise sessions.

Conditions

  • Handball Players

Interventions

DIETARY_SUPPLEMENT

Olive leaf extract

OLE supplement (500 mg, standardized to 25% oleuropein)

OTHER

Placebo

Sucrose capsules with the same color, scent, and size as OLE capsules.

Sponsors & Collaborators

  • Karabuk University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
25 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-01-01
Primary Completion
2025-01-15
Completion
2025-02-01

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07371052 on ClinicalTrials.gov